Applying New Evidence to Optimize Care in Advanced Prostate Cancer
  • CME

Gain expert insights on the latest clinical data informing optimal care of patients with advanced prostate cancer using new therapeutic strategies.
Matthew R. Smith, MD, PhD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: October 8, 2020 Expiration: October 7, 2021

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply expert recommendations for the sequencing of available and emerging hormonal, cytotoxic, immunologic, bone-directed, molecularly targeted, and other novel therapies (alone and in combination) to safely and effectively integrate them into the care of patients with metastatic castration-resistant prostate cancer
  • Evaluate new therapeutic options for nonmetastatic castration-resistant prostate cancer
  • Plan optimal, individualized therapeutic strategies for M0 or metastatic hormone-sensitive prostate cancer
  • Assess and manage the risk for cardiotoxicity or bone loss previous to and/or during prostate cancer treatment
  • Refer appropriate patients with prostate cancer to ongoing clinical trials assessing novel therapies alone and in combination throughout the disease continuum to aid in trial enrollment

Acknowledgements

Provided by the USF Health in partnership with Clinical Care Options.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Astellas
Bayer HealthCare Pharmaceuticals Inc.
Pfizer
Sanofi Genzyme Corporation

Information on this Educational Activity

Faculty

Matthew R. Smith, MD, PhD

Claire and John Bertucci Endowed Chair in Genitourinary Cancers
Professor of Medicine,
Harvard Medical School
Director, Genitourinary Malignancies Program
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Matthew R. Smith, MD, PhD, has disclosed that he has served on the advisory board and received consulting fees from Amgen, Astellas, Bayer, Janssen, and Lilly, and received funds for research support paid to his institution from Amgen, Arvinas, Bayer, and Janssen, and Lilly.

Staff

Marie N. Becker, PhD

Scientific Director

Marie N. Becker, PhD, has no relevant conflicts of interest to report.
Bing-e Xu, PhD

Scientific Director

Bing-E Xu, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Jim Mortimer

Senior Director, Oncology Programs and Partnership Development

Jim Mortimer has disclosed that his spouse/partner has ownership interest (stock) in AstraZeneca.
Krista Marcello

Associate Director, Educational Strategy

Krista Marcello has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

USF Health OCPD staff have no relevant conflicts of interest to report.

Target Audience

This program is intended for physicians, pharmacists, oncology nurses, and other healthcare providers who care for patients with prostate cancer.

Goal

The goal of this activity is to improve learners’ knowledge and competence in, as well as performance at applying, practice-changing clinical data and expert recommendations to optimize the care of men with prostate cancer.

USF Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

Physician Continuing Medical Education

Credit Designation

USF Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 08, 2020, through October 07, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Cabozantinib plus atezolizumab suggested encouraging anticancer activity in metastatic castration-resistant prostate cancer; ESMO coverage from Clinical Care Options (CCO)

person default Eva Ciruelos, MD, PhD Karim Fizazi, MD, PhD Eric Van Cutsem, MD, PhD person default Vamsidhar Velcheti, MD Released: September 21, 2021

Download this short slideset from Clinical Care Options (CCO) the use of androgen deprivation therapy for nonmetastatic or metastatic prostate cancer

Daniel W. Lin, MD Alicia K. Morgans, MD, MPH David F. Penson, MD Released: September 20, 2021

Experts highlight key studies being presented at the upcoming 2021 ESMO Congress in this commentary from Clinical Care Options (CCO)

person default Eva Ciruelos, MD, PhD Karim Fizazi, MD, PhD Eric Van Cutsem, MD, PhD person default Vamsidhar Velcheti, MD Released: September 15, 2021

Slides from Clinical Care Options (CCO) on 2021 treatment recommendations for patients with nmCRPC.

David F. Penson, MD Released: September 10, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue